Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Alfresa, Kidswell, and Others to Form JV for Biosimilar Production in Japan
October 7, 2025
- Gilead Opens Japan Facility to Support CAR-T Delivery
October 7, 2025
- Datroway Hits Key Goals in Global PIII Trial for TNBC: Daiichi Sankyo
October 7, 2025
- SymBio Kicks Off Global PIII Trial of Brincidofovir in Europe
October 7, 2025
- Keytruda Maintains No. 1 Spot for 24th Straight Month: Encise
October 7, 2025
- Takeda Pulls Plug on Cell Therapy Work after Strategy Review
October 6, 2025
- LEO Pharma Begins Promotional Activities for Spevigo in Japan
October 6, 2025
- Sanofi Files ITP Drug Rilzabrutinib in Japan
October 6, 2025
- Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns
October 3, 2025
- Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground
October 3, 2025
- Argenx Puts Japan at Core of Global Innovation Strategy
October 3, 2025
- Daiichi Sankyo Opens Third Overseas Research Hub in San Diego
October 3, 2025
- Enhertu Accepted for US Review in Pre-Surgery Setting for Early Breast Cancer
October 3, 2025
- Ziftomenib Given in New AML Cohort in US PI Trial: Kura/Kyowa Kirin
October 3, 2025
- HIV Support Groups Call for Stronger Mail-In Testing System in Japan
October 3, 2025
- Dayvigo, Jardiance Keep Up Strong Promotion in August: Intage
October 3, 2025
- AbbVie Aims for Neuroscience Leadership, CSO Says in Tokyo
October 2, 2025
- Kyorin Bags Japan Rights to Hinge Bio’s SLE Med
October 2, 2025
- JCR Out-Licenses Fabry Drug to Oman’s Menagen for MENAT Region
October 2, 2025
- Specialist Urges More COVID Shots for Elderly amid “13th Wave”
October 2, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…